ClinicalTrials.gg
CompletedNCT06389487Updated Sep 25, 2025Results posted

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

A Phase 3 interventional study of RSVPreF3 OA investigational vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 52 sites in 6 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,459
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.

Enrollment
6th of 17
1,459 · median 976
Started
2024
with 6 others
Phase 3
15 of 17
none open now
Registered
11th of 17
by date
Lead sponsor
15 of 17
GlaxoSmithKline

Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 6th largest by enrollment, is one of 7 that started in 2024, is one of 15 in phase 3, and was the 11th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About arexvy

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing arexvy in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

The aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV disease, compared to older adults (OA) 60 YOA and above.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory Syncytial Virus (RSV)
  • Immunogenicity
  • Safety
  • Non-inferiority
  • Humoral immune response
  • At increased risk (AIR)
  • Older Adults
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants and/or participant's parent(s)/ Legally acceptable representative (LAR) who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, attend study site visits, ability to access and utilize a phone or other electronic communications).
  • Written or witnessed obtained from the participant/participant's parent(s)/LAR(s) (participant must be able to understand the informed consent) prior to performance of any study-specific procedure.

Written informed assent obtained from the participant (participant must be able to understand the informed assent) if he/she is less than the legal age prior to performance of any study-specific procedure.

Specific inclusion criteria for all participants in Cohort 1 and Cohort 3 (RSV-A-AIR Group) • A male or female participant 18-49 YOA at the time of the study intervention administration.

  • Participants should be diagnosed with at least 1 of the following medical conditions if considered medically stable by the investigator:

    • Chronic cardiopulmonary disease resulting in activity restricting symptoms or use of long term medication:

      o (COPD)

      o Asthma

      o Cystic fibrosis

      o Other chronic respiratory diseases: lung fibrosis, restrictive lung disease, interstitial lung disease, emphysema or bronchiectasis

      o Chronic heart failure:

      o Pre-existing Coronary Artery Disease (CAD) (CAD not otherwise specified)

      • Cardiac arrhythmia
    • Diabetes mellitus: types 1 or 2 with active treatment for the past 6 months
    • Other diseases at increased risk for RSV disease:

      • Chronic kidney disease
      • Chronic moderate to severe liver disease
      • Neurologic or neuromuscular conditions
  • Female participants of non- may be enrolled in the study. Non-childbearing potential is defined as premenarche, hysterectomy, bilateral oophorectomy, bilateral salpingectomy or .
  • Female participants of childbearing potential may be enrolled in the study, if the participant:

    • has practiced adequate from 1 month prior to study intervention administration, and
    • has a negative pregnancy test on the day of study prior to intervention administration, and
    • has agreed to continue adequate contraception for at least 1 month after completion of the study intervention administration.

Specific inclusion criteria for all participants in Cohort 2 (RSV-OA Group):

  • A male or female participant >=60 YOA at the time of the study intervention administration.

Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease are allowed to participate in this study if considered medically stable by the investigator.

  • Participants living in the general community or in an assisted-living facility that provides minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Any confirmed or suspected or immunodeficient condition resulting from disease (e.g., current , ) or immunosuppressive/cytotoxic therapy (e.g., medication used during cancer chemotherapy, organ transplantation, or to treat disorders), based on medical history and physical examination (no laboratory testing required).
  • History of any reaction or likely to be exacerbated by any component of the study intervention.
  • Unstable chronic illness.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.
  • Recurrent or uncontrolled neurological disorders or seizures. Participants with medically controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol (e.g., completion of the diary cards, attend study site visits). Study participants may decide to assign a caregiver to help them complete the study procedures.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life-threatening disease).
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.

Prior/Concomitant therapy

  • Use of any or non-registered product (drug, vaccine, or medical device) other than the study intervention during the period beginning 30 days before the dose of study intervention (Day -29 to Day 1), or planned use during the study period (up to Visit 3, Month 6).
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after the dose of study intervention administration, with the exception of inactivated, subunit and split influenza vaccines or COVID-19 vaccines which can be administered up to 14 days before or from 14 days after the study intervention administration.
  • Previous vaccination with any RSV vaccine, including investigational RSV vaccines.
  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or administration of long-acting immune-modifying treatments or planned administration at any time up to the End-of-study (EOS).

    • Up to 3 months prior to the study intervention administration:

      • For , this will mean prednisone >=20 mg/day, or equivalent. Inhaled, topical and intra-articular steroids are allowed
      • Administration of immunoglobulins and/or any blood products or plasma derivatives
    • Up to 6 months prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., Tumor Necrosis Factor (TNF)-inhibitors), monoclonal antibodies, antitumoral medication.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or invasive medical device).

Other exclusions:

Other exclusions for all participants:

  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Bedridden participants.
  • Planned move during the study period that will prohibit participating in the study until study end.
  • Participation of any study personnel or their immediate dependents, family, or household members.

Other exclusions for Cohort 1 and Cohort 3:

  • Pregnant or lactating female participant.
  • Female planning to become pregnant or planning to discontinue precautions within 1 month after study intervention administration.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,459 participants (actual)

Study arms

  • Experimental
    Part A: RSV-A-AIR Group

    Adult (A) participants, 18-49 YOA, at increased risk (AIR) for RSV disease, received a single dose of RSVPreF3 OA investigational vaccine at Day 1. Participants in this group were considered for all study analyses, as per protocol.

    Biological: RSVPreF3 OA investigational vaccine

  • Active comparator
    Part A: RSV-OA Group

    Older adults (OA) participants, ≥60 YOA, received a single dose of RSVPreF3 OA investigational vaccine at Day 1.

    Biological: RSVPreF3 OA investigational vaccine

  • Experimental
    Part B: RSV-A-AIR Group

    Adult participants, 18-49 YOA, AIR for RSV disease, received a single dose of RSVPreF3 OA investigational vaccine at Day 1. Participants in this group were considered only for Participant flow, Baseline Characteristics and all safety analyses, as per protocol.

    Biological: RSVPreF3 OA investigational vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)

    RSV-A neutralizing titers are given as group GMTs and are expressed as Estimated dilution 60 (ED60)

    Time frame: At Day 31

  2. Part A: Percentage of Participants With Seroresponse Rate (SRR) in RSV-A Neutralizing Titers

    SRR is defined as the percentage of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) ≥4. RSV-A neutralizing titers are expressed as ED60.

    Time frame: Day 31 compared with baseline (Day 1)

  3. Part A: RSV-B Neutralizing Titers Expressed as Group GMTs

    RSV-B neutralizing titers are given as group GMTs and are expressed as ED60.

    Time frame: At Day 31

  4. Part A: Percentage of Participants With SRR in RSV-B Neutralizing Titers

    SRR is defined as the percentage of participants having a fold increase in neutralizing titers (1-month post-study intervention administration over pre-study intervention administration) ≥ 4. RSV-B neutralizing titers are expressed as ED60.

    Time frame: Day 31 compared with baseline (Day 1)

Secondary outcomes

  1. Part A and B: Number of Participants Reporting Any Solicited Administration Site Events

    Assessed solicited administration site events were pain, redness (erythema) and swelling at administration site. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: Day 1 (post dose) to Day 4

  2. Part A and B: Number of Participants Reporting Any Solicited Systemic Events

    Assessed solicited systemic events were fever (pyrexia), headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness). Fever was defined as temperature ≥38.0 degrees Celsius (°C), regardless of the location of measurement. The route for measuring temperature could be oral or axillary. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: Day 1 (post dose) to Day 4

  3. Part A and B: Number of Participants Reporting Unsolicited Adverse Events (AEs)

    An unsolicited AE wass an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs included both serious and non-serious AEs.

    Time frame: Day 1 (post dose) to Day 30

  4. Part A and B: Number of Participants Reporting Any Serious Adverse Events (SAEs), Related SAEs and Fatal SAEs

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes. Any SAE = occurrence of the SAE regardless of the intensity grade or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination.

    Time frame: Throughout the study period (Day 1 to Month 6)

  5. Part A and B: Number of Participants Reporting Any Adverse Events of Special Interest (AESIs)

    AESIs assessed were potential immune-mediated diseases (pIMDs) and atrial fibrillation (AF). pIMDs were a subset of AESIs that included autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. AEs of AF were considered as AESI.

    Time frame: Throughout the study period (Day 1 to Month 6)

  6. Part A: RSV-A Neutralizing Titers Expressed as GMTs

    RSV-A neutralizing titers are given as GMTs and are expressed as ED60.

    Time frame: At Day 1 (pre-dose), at Month 1 and Month 6

  7. Part A: RSV-B Neutralizing Titers Expressed as GMTs

    RSV-B neutralizing titers are given as GMTs and are expressed as ED60.

    Time frame: At Day 1 (pre-dose), at Month 1 and Month 6

07

Results

Posted Sep 25, 2025

Participant flow

Participant flow — Overall Study
MilestonePart A: RSV-A-AIR GroupPart A: RSV-OA GroupPart B: RSV-A-AIR Group
Started426429603
Completed414422586
Not completed12717
Withdrew: Lost to follow-up9513
Withdrew: Protocol violation002
Withdrew: Withdrawal by subject221
Withdrew: Other101

Outcome measures

PrimaryPart A: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)

RSV-A neutralizing titers are given as group GMTs and are expressed as Estimated dilution 60 (ED60)

Time frame:
At Day 31
Reported as:
Geometric mean · Titer
Part A: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)
TiterPart A: RSV-A-AIR GroupPart A: RSV-OA Group
Part A: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)11910.1 (10927.3 to 12981.4)8593.6 (7904.3 to 9343.0)
Statistical analysis
  • Part A: RSV-A-AIR Group vs Part A: RSV-OA Group · Gmt ratio: 0.72 · 95% CI 0.64 to 0.81The comparison is done using the group ratio of adjusted GMT (Part A:RSV-OA/ Part A:RSV-A-AIR) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
PrimaryPart A: Percentage of Participants With Seroresponse Rate (SRR) in RSV-A Neutralizing Titers

SRR is defined as the percentage of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) ≥4. RSV-A neutralizing titers are expressed as ED60.

Time frame:
Day 31 compared with baseline (Day 1)
Reported as:
Number · Percentage of participants
Part A: Percentage of Participants With Seroresponse Rate (SRR) in RSV-A Neutralizing Titers
Percentage of participantsPart A: RSV-A-AIR GroupPart A: RSV-OA Group
Part A: Percentage of Participants With Seroresponse Rate (SRR) in RSV-A Neutralizing Titers87.0 (83.3 to 90.2)77.7 (73.4 to 81.6)
Statistical analysis
  • Part A: RSV-A-AIR Group vs Part A: RSV-OA Group · Difference in percentage: -9.33 · 95% CI -14.55 to -4.10The comparison is done using the difference of SRR (Part A:RSV-OA - Part A:RSV-A-AIR).
PrimaryPart A: RSV-B Neutralizing Titers Expressed as Group GMTs

RSV-B neutralizing titers are given as group GMTs and are expressed as ED60.

Time frame:
At Day 31
Reported as:
Geometric mean · Titer
Part A: RSV-B Neutralizing Titers Expressed as Group GMTs
TiterPart A: RSV-A-AIR GroupPart A: RSV-OA Group
Part A: RSV-B Neutralizing Titers Expressed as Group GMTs12496.4 (11482.4 to 13599.9)9089.7 (8373.7 to 9866.9)
Statistical analysis
  • Part A: RSV-A-AIR Group vs Part A: RSV-OA Group · Gmt ratio: 0.73 · 95% CI 0.65 to 0.82The comparison is done using the group ratio of adjusted GMT (Part A:RSV-OA/ Part A:RSV-A-AIR) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
PrimaryPart A: Percentage of Participants With SRR in RSV-B Neutralizing Titers

SRR is defined as the percentage of participants having a fold increase in neutralizing titers (1-month post-study intervention administration over pre-study intervention administration) ≥ 4. RSV-B neutralizing titers are expressed as ED60.

Time frame:
Day 31 compared with baseline (Day 1)
Reported as:
Number · Percentage of participants
Part A: Percentage of Participants With SRR in RSV-B Neutralizing Titers
Percentage of participantsPart A: RSV-A-AIR GroupPart A: RSV-OA Group
Part A: Percentage of Participants With SRR in RSV-B Neutralizing Titers87.2 (83.5 to 90.4)77.2 (72.9 to 81.2)
Statistical analysis
  • Part A: RSV-A-AIR Group vs Part A: RSV-OA Group · Difference in percentage: -10.03 · 95% CI -15.26 to -4.80The comparison is done using the difference of SRR (Part A:RSV-OA - Part A:RSV-A-AIR).
SecondaryPart A and B: Number of Participants Reporting Any Solicited Administration Site Events

Assessed solicited administration site events were pain, redness (erythema) and swelling at administration site. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
Day 1 (post dose) to Day 4
Reported as:
Count of participants · Participants
Part A and B: Number of Participants Reporting Any Solicited Administration Site Events
ParticipantsPart A: RSV-A-AIR GroupPart A: RSV-OA GroupPart B: RSV-A-AIR Group
Pain358246422
Redness362352
Swelling251947
SecondaryPart A and B: Number of Participants Reporting Any Solicited Systemic Events

Assessed solicited systemic events were fever (pyrexia), headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness). Fever was defined as temperature ≥38.0 degrees Celsius (°C), regardless of the location of measurement. The route for measuring temperature could be oral or axillary. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
Day 1 (post dose) to Day 4
Reported as:
Count of participants · Participants
Part A and B: Number of Participants Reporting Any Solicited Systemic Events
ParticipantsPart A: RSV-A-AIR GroupPart A: RSV-OA GroupPart B: RSV-A-AIR Group
Fever251126
Headache19878250
Myalgia284169331
Arthralgia12478167
Fatigue275148337
SecondaryPart A and B: Number of Participants Reporting Unsolicited Adverse Events (AEs)

An unsolicited AE wass an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs included both serious and non-serious AEs.

Time frame:
Day 1 (post dose) to Day 30
Reported as:
Count of participants · Participants
Part A and B: Number of Participants Reporting Unsolicited Adverse Events (AEs)
ParticipantsPart A: RSV-A-AIR GroupPart A: RSV-OA GroupPart B: RSV-A-AIR Group
Part A and B: Number of Participants Reporting Unsolicited Adverse Events (AEs)7276118
SecondaryPart A and B: Number of Participants Reporting Any Serious Adverse Events (SAEs), Related SAEs and Fatal SAEs

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes. Any SAE = occurrence of the SAE regardless of the intensity grade or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination.

Time frame:
Throughout the study period (Day 1 to Month 6)
Reported as:
Count of participants · Participants
Part A and B: Number of Participants Reporting Any Serious Adverse Events (SAEs), Related SAEs and Fatal SAEs
ParticipantsPart A: RSV-A-AIR GroupPart A: RSV-OA GroupPart B: RSV-A-AIR Group
Any SAEs41310
Related SAEs000
Fatal SAEs000
SecondaryPart A and B: Number of Participants Reporting Any Adverse Events of Special Interest (AESIs)

AESIs assessed were potential immune-mediated diseases (pIMDs) and atrial fibrillation (AF). pIMDs were a subset of AESIs that included autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. AEs of AF were considered as AESI.

Time frame:
Throughout the study period (Day 1 to Month 6)
Reported as:
Count of participants · Participants
Part A and B: Number of Participants Reporting Any Adverse Events of Special Interest (AESIs)
ParticipantsPart A: RSV-A-AIR GroupPart A: RSV-OA GroupPart B: RSV-A-AIR Group
Part A and B: Number of Participants Reporting Any Adverse Events of Special Interest (AESIs)122
SecondaryPart A: RSV-A Neutralizing Titers Expressed as GMTs

RSV-A neutralizing titers are given as GMTs and are expressed as ED60.

Time frame:
At Day 1 (pre-dose), at Month 1 and Month 6
Reported as:
Geometric mean · Titer
Part A: RSV-A Neutralizing Titers Expressed as GMTs
TiterPart A: RSV-A-AIR GroupPart A: RSV-OA Group
Day 1892.6 (821.5 to 969.9)913.8 (837.2 to 997.4)
Month 111853.4 (10875.3 to 12919.5)8632.4 (7858.3 to 9482.6)
Month 64439.8 (4042.1 to 4876.7)3917.7 (3553.0 to 4319.7)
SecondaryPart A: RSV-B Neutralizing Titers Expressed as GMTs

RSV-B neutralizing titers are given as GMTs and are expressed as ED60.

Time frame:
At Day 1 (pre-dose), at Month 1 and Month 6
Reported as:
Geometric mean · Titer
Part A: RSV-B Neutralizing Titers Expressed as GMTs
TiterPart A: RSV-A-AIR GroupPart A: RSV-OA Group
Day 1988.1 (905.9 to 1077.8)1045.1 (953.7 to 1145.2)
Month 112337.6 (11334.3 to 13429.7)9178.5 (8367.7 to 10067.8)
Month 64335.6 (3941.7 to 4769.0)4355.0 (3971.4 to 4775.7)

Adverse events

Collected over Solicited AEs were collected from Day 1 (day of vaccination) up to Day 4 post-dose. Unsolicited AEs were collected from Day 1 up to Day 30 post-dose. All-cause mortality, SAEs, related SAEs, fatal SAEs and AESIs (including pIMDs and AF) were collected from Day 1 up to study end (Month 6). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: RSV-A-AIR Group0/426 (0%)4/426 (0.9%)386/426 (90.6%)
Part A: RSV-OA Group0/429 (0%)13/429 (3%)310/429 (72.3%)
Part B: RSV-A-AIR Group0/603 (0%)10/603 (1.7%)483/603 (80.1%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPart A: RSV-A-AIR GroupPart A: RSV-OA GroupPart B: RSV-A-AIR Group
GastroenteritisInfections and infestations1/4260/4290/603
Pulmonary sepsisInfections and infestations1/4260/4290/603
Acute myocardial infarctionCardiac disorders1/4260/4290/603
AngioedemaSkin and subcutaneous tissue disorders1/4260/4290/603
CellulitisInfections and infestations0/4261/4291/603
PneumoniaInfections and infestations0/4261/4290/603
SepsisInfections and infestations0/4261/4290/603
Neurological symptomNervous system disorders0/4261/4290/603
Transient global amnesiaNervous system disorders0/4261/4290/603
Transient ischaemic attackNervous system disorders0/4261/4290/603
Most frequent other events
Showing 10 of 149
Most frequent other events
EventPart A: RSV-A-AIR GroupPart A: RSV-OA GroupPart B: RSV-A-AIR Group
Injection site painGeneral disorders358/426246/429422/603
MyalgiaMusculoskeletal and connective tissue disorders284/426169/429331/603
FatigueGeneral disorders275/426148/429338/603
HeadacheNervous system disorders198/42678/429250/603
ArthralgiaMusculoskeletal and connective tissue disorders126/42681/429167/603
Injection site erythemaGeneral disorders37/42623/42952/603
Injection site swellingGeneral disorders25/42619/42947/603
PyrexiaGeneral disorders26/42612/42929/603
NauseaGastrointestinal disorders14/4262/42912/603
ChillsGeneral disorders5/4262/42913/603

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Part A: RSV-A-AIR GroupPart A: RSV-OA GroupPart B: RSV-A-AIR GroupTotal
Mean38.9 ± 7.868.6 ± 5.738.1 ± 8.747.3 ± 15.7
Sex: Female, Male
Sex: Female, Male(Participants)Part A: RSV-A-AIR GroupPart A: RSV-OA GroupPart B: RSV-A-AIR GroupTotal
Female247220347814
Male179209256644
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: RSV-A-AIR GroupPart A: RSV-OA GroupPart B: RSV-A-AIR GroupTotal
American Indian or Alaska Native801119
Asian605064174
Balck or African American7754181312
Native Hawaiian or Other Pacific Islander001111
White255302274831
Not reported3104
Unknown4037
Multiple Race Categories192259100
08

Study locations

52 sites
  • GSK Investigational Site
    Glendale, Arizona 85308, United States
  • GSK Investigational Site
    Phoenix, Arizona 85284, United States
  • GSK Investigational Site
    North Hollywood, California 91606-3287, United States
  • GSK Investigational Site
    Oakland, California 94610, United States
  • GSK Investigational Site
    Walnut Creek, California 94598, United States
  • GSK Investigational Site
    Hialeah, Florida 33012, United States
  • GSK Investigational Site
    North Miami, Florida 33173, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Lexington, Kentucky 40509, United States
  • GSK Investigational Site
    Silver Spring, Maryland 20904, United States
  • GSK Investigational Site
    Rochester, New York 14609, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73111, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37909, United States
  • GSK Investigational Site
    DeSoto, Texas 75115, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22911, United States
  • GSK Investigational Site
    Wenatchee, Washington 98801, United States
  • GSK Investigational Site
    Coffs Harbour, New South Wales 2450, Australia
  • GSK Investigational Site
    Sydney, New South Wales 2010, Australia
  • GSK Investigational Site
    Sydney, New South Wales 2065, Australia
  • GSK Investigational Site
    Fortitude Valley, Queensland 4006, Australia
  • GSK Investigational Site
    Tarragindi, Queensland 4121, Australia
  • GSK Investigational Site
    Melbourne, Victoria 3051, Australia
  • GSK Investigational Site
    St Albans, Victoria 3021, Australia
  • GSK Investigational Site
    New Westminster, British Columbia V3L 3W4, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8V 4A1, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    Greater Sudbury, Ontario P3C 1X3, Canada
  • GSK Investigational Site
    Guelph, Ontario N1G 0B4, Canada
  • GSK Investigational Site
    London-Ontario, Ontario N5W 6A2, Canada
  • GSK Investigational Site
    Toronto, Ontario M4G 3E8, Canada
  • GSK Investigational Site
    Québec, Quebec G1N 4V3, Canada
  • GSK Investigational Site
    Québec, Quebec G1V 4G2, Canada
  • GSK Investigational Site
    Québec, Quebec G1V 4W2, Canada
  • GSK Investigational Site
    Saint-Charles-Borromée, Quebec J6E 2B4, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1J 2G2, Canada
  • GSK Investigational Site
    Weinheim, Baden-Wurttemberg 69469, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 13347, Germany
  • GSK Investigational Site
    Essen, 45355, Germany
  • GSK Investigational Site
    Mainz, 55116, Germany
  • GSK Investigational Site
    Wallerfing, 94574, Germany
  • GSK Investigational Site
    Witten, 58455, Germany
  • GSK Investigational Site
    Würzburg, 97070, Germany
  • GSK Investigational Site
    Ibaraki, 300-0062, Japan
  • GSK Investigational Site
    Kanagawa, 211-0041, Japan
  • GSK Investigational Site
    Tokyo, 155-0031, Japan
  • GSK Investigational Site
    Tokyo, 180-0022, Japan
  • GSK Investigational Site
    Cape Town, 7530, South Africa
  • GSK Investigational Site
    Cape Town, 7700, South Africa
  • GSK Investigational Site
    Johannesburg, 2113, South Africa
  • GSK Investigational Site
    Reiger Park, 1459, South Africa
09

References and documents

Publications

  • Mitha E, Ferguson M, Wilhase AC, De Looze F, Vachon ML, Stacey H, Rasalam R, Nozaki M, Smith WB, Schwarz TF, Hailemariam HA, Deraedt Q, Gerard C, Vanden Abeele C, Damaso S, Descamps D, Hill J, Dasyam D, Van Gucht J, Hulstrom V. Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged >/=60 Years. Clin Infect Dis. 2026 May 20;82(5):e1093-e1103. doi: 10.1093/cid/ciag058. PubMed 41757519 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer tohttps://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jul 2024, 3 months.

Results were first posted in Sep 2025, 1 year 1 month after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 3 months is below that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2024
First posted
Apr 29, 2024
StartActual
Apr 29, 2024
Primary completionActual
Jul 29, 2024
CompletionActual
Mar 18, 2025
Results first posted
Sep 25, 2025
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06389487
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
Apr 29, 2024
Primary completion
Jul 29, 2024
Completion
Mar 18, 2025
Results posted
Sep 25, 2025
Last update
Sep 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arexvy

Start the discussion